AbbVie Inc. Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax
AbbVie Inc. (ABBV) reported Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax of $12.00 million for the 3-month period ending 2021-06-30, per its 10-Q filed 2021-08-02.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax · last filed 2021-08-02
- AbbVie Inc. other comprehensive income (loss), derivatives qualifying as hedges, net of tax for the quarter ending 2021-06-30 was $12.00M.
- AbbVie Inc. other comprehensive income (loss), derivatives qualifying as hedges, net of tax for the quarter ending 2021-03-31 was $46.00M.
- AbbVie Inc. other comprehensive income (loss), derivatives qualifying as hedges, net of tax for the quarter ending 2020-12-31 was -$63.00M, a 136.42% decline year-over-year.
- AbbVie Inc. other comprehensive income (loss), derivatives qualifying as hedges, net of tax for the quarter ending 2020-09-30 was -$57.00M, a 283.87% decline year-over-year.
- AbbVie Inc. other comprehensive income (loss), derivatives qualifying as hedges, net of tax for fiscal 2020 was -$131.00M, a 192.91% decline from fiscal 2019.
- AbbVie Inc. other comprehensive income (loss), derivatives qualifying as hedges, net of tax for fiscal 2019 was $141.00M, a 54.95% decline from fiscal 2018.
- AbbVie Inc. other comprehensive income (loss), derivatives qualifying as hedges, net of tax for fiscal 2018 was $313.00M.
| Period end | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax 3 month | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax 6 month | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax 9 month | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax 12 month |
|---|---|---|---|---|
| 2021-06-30 | $12.00M 10-Q · filed 2021-08-02 | $58.00M 10-Q · filed 2021-08-02 | -$5.00M derived: sum of 3 quarters · filed 2021-08-02 | -$62.00M derived: sum of 4 quarters · filed 2021-08-02 |
| 2021-03-31 | $46.00M 10-Q · filed 2021-05-07 | -$17.00M derived: sum of 2 quarters · filed 2021-05-07 | -$74.00M derived: sum of 3 quarters · filed 2021-05-07 | -$83.00M derived: sum of 4 quarters · filed 2021-08-02 |
| 2020-12-31 | -$63.00M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-19 | -$120.00M derived: sum of 2 quarters · filed 2021-02-19 | -$129.00M derived: sum of 3 quarters · filed 2021-08-02 | -$131.00M 10-K · filed 2021-02-19 |
| 2020-09-30 | -$57.00M 10-Q · filed 2020-11-04 | -$66.00M derived: sum of 2 quarters · filed 2021-08-02 | -$68.00M 10-Q · filed 2020-11-04 | $105.00M derived: sum of 4 quarters · filed 2021-08-02 |
| 2020-06-30 | -$9.00M 10-Q · filed 2021-08-02 | -$11.00M 10-Q · filed 2021-08-02 | $162.00M derived: sum of 3 quarters · filed 2021-08-02 | $193.00M derived: sum of 4 quarters · filed 2021-08-02 |
| 2020-03-31 | -$2.00M 10-Q · filed 2021-05-07 | $171.00M derived: sum of 2 quarters · filed 2021-05-07 | $202.00M derived: sum of 3 quarters · filed 2021-05-07 | $169.00M derived: sum of 4 quarters · filed 2021-05-07 |
| 2019-12-31 | $173.00M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-19 | $204.00M derived: sum of 2 quarters · filed 2021-02-19 | $171.00M derived: sum of 3 quarters · filed 2021-02-19 | $141.00M 10-K · filed 2021-02-19 |
| 2019-09-30 | $31.00M 10-Q · filed 2020-11-04 | -$2.00M derived: sum of 2 quarters · filed 2020-11-04 | -$32.00M 10-Q · filed 2020-11-04 | |
| 2019-06-30 | -$33.00M 10-Q · filed 2020-08-04 | -$63.00M 10-Q · filed 2020-08-04 | ||
| 2018-12-31 | $313.00M 10-K · filed 2021-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |